tag long-term-treatment 
Pharmaceutical Technology
MAY 19, 2023
Currently, most patients face the prospect of life-long treatment with MS medications, as the main objectives of available disease-modifying therapies (DMTs) are to reduce the frequency of relapses and to delay the accumulation of disability. DMTs for MS have a high price tag, particularly in the US.
pharmaphorum
JANUARY 9, 2023
Since 2020, the global SMA treatment landscape has progressed, with three treatments now approved, according to Novartis. ” Zolgensma is one of the most expensive therapies available, with a price tag of around $2.1 ” Zolgensma is one of the most expensive therapies available, with a price tag of around $2.1
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MAY 2, 2023
Immuno-oncology (IO) agents have transformed the cancer therapeutics landscape, driving long-term remissions in a subset of patients who historically had limited options. Efficacy-related unmet needs included the need for a greater long-term benefit, higher response rates, and mechanisms for overcoming resistance to IO therapies.
pharmaphorum
JUNE 2, 2022
R&D into orphan drugs is growing alongside the number of approved treatments, providing treatments for rare diseases that previously did not have any. As covered in a previous article , the importance of R&D to develop treatments for rare diseases is high. It is estimated that between 3.5 The price is right.
pharmaphorum
NOVEMBER 16, 2022
The advancements made in drug development over the last decade have seen the arrival of a number of treatments that offer one-time cures and more effective therapies for conditions in smaller patient populations. Advanced therapies have changed the treatment landscape for the industry and for patients. Changing the model.
European Pharmaceutical Review
MAY 11, 2023
Novartis shared long-term data for its SMA gene therapy in March 2023, which indicated significant long-term motor-milestone achievements in spinal muscular atrophy (SMA). There are three modes of action (MOA) available for treatments – intrathecal injection, intravenous infusion and an oral formula.
pharmaphorum
FEBRUARY 16, 2021
There is a curative treatment for people who rely on blood transfusions to survive and maintain their levels of red blood cells. In this first draft guidance NICE raised a series of issues with Zynteglo, which bluebird has already agreed to supply at a confidential discount from its hefty price tag, which is around €1.57
Expert insights. Personalized for you.
98 
Let's personalize your content